Article metrics
PDF
Other content recommended for you
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design
- What is CAR T-cell therapy?
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
- Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
- Cardiotoxicities of novel cancer immunotherapies